Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System
The DOI matches its Crossref record; 49 of the 53 references it cites were found in a registry or an index.
Abstract
The Biopharmaceutics Classification System (BCS) was developed to allow prediction of in vivo pharmacokinetic performance of drug products from measurements of permeability (determined as the extent of oral absorption) and solubility. Here, we suggest that a modified version of such a classification system may be useful in predicting overall drug disposition, including routes of drug elimination and the effects of efflux and absorptive transporters on oral drug absorption; when transporter-enzyme interplay will yield clinically significant effects (e.g., low bioavailability and drug-drug interactions); the direction, mechanism, and importance of food effects; and transporter effects on postabsorption systemic drug concentrations following oral and intravenous dosing. These predictions are supported by a series of studies from our laboratory during the past few years investigating the effect of transporter inhibition and induction on drug metabolism. We conclude by suggesting that a Biopharmaceutics Drug Disposition Classification System (BDDCS) using elimination criteria may expand the number of Class 1 drugs eligible for a waiver of in vivo bioequivalence studies and provide predictability of drug disposition profiles for Classes 2, 3, and 4 compounds.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) govern intestinal absorption, biliary excretion, and central nervous system penetration, and their expression, tissue localization, and substrate affinity differ appreciably between rodents, dogs, non-human primates, and humans; body-weight scaling captures none of this, whereas the Extended Clearance Classification Syst”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [45]
In the citing paper
“ECCS provides a priori insight into whether a compound’s clearance is likely dominated by CYP-mediated metabolism (where allometric scaling with IVIVE tends to perform well), renal filtration (where GFR-based scaling is appropriate), or transporter-mediated hepatic uptake or biliary excretion (where simple allometry may fail).”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [45]
In the citing paper
“The framework thus helps practitioners decide, before data are generated, which scaling approach is most likely to yield reliable human predictions and where additional mechanistic studies may be needed [41,42,45].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [45]
In the citing paper
“ECCS builds on the foundational Biopharmaceutics Drug Disposition Classification System (BDDCS) framework articulated by Wu and Benet, which first formalized the interplay between permeability, solubility, transporters, and metabolism in shaping disposition [45].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [45]
In the citing paper
“Because the ECCS, and the related BDDCS, classify a compound from its physicochemical and in vitro properties (molecular weight, ionization, and passive permeability for the ECCS; solubility, permeability, and the extent of metabolism for the BDDCS), the class can be assigned before any human data are generated and is therefore available at the first-in-human stage [41,45].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [45]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“We anticipate that the DPR will have components related to physicochemical parameters [such as Lipinski Rule of 5 characteristics and parameters related to polar surface area and/or molecular flexibility (22,23,52)], together with qualifications related to uptake (and efflux) transporters, and a parameter related to t…”
BackgroundGoodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430 · cited 1×
“Amidon and co-workers (1) recognized that the fundamental parameters controlling the rate and extent of oral drug absorption were the drug’s aqueous solubility and gastrointestinal permeability.”
BackgroundDrug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540120077042 · Cited by 2,371
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Thompson Coon, J. (2002) · Focus on Alternative and Complementary Therapies · doi:10.1111/j.2042-7166.2002.tb05480.x · Cited by 1,744
Lindenberg, M., Kopp, S., & Dressman, J. B. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.001 · Cited by 864
Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification
Kasim, N. A., Whitehouse, M., Ramachandran, C., Bermejo, M., Lennernäs, H., Hussain, A. S., Junginger, H. E., Stavchansky, S. A., Midha, K. K., Shah, V. P., et al. (2004) · Molecular Pharmaceutics · doi:10.1021/mp034006h · Cited by 847
(2001) · Drugs and the Pharmaceutical Sciences · doi:10.1201/9780824741969.axh · Cited by 818
Löbenberg, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00091-6 · Cited by 729
Dresser, G. K., Bailey, D. G., Leake, B. F., Schwarz, U. I., Dawson, P. A., Freeman, D. J., & Kim, R. B. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121152 · Cited by 606
OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine
Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15235-x · Cited by 597
Physicochemical Profiling (Solubility, Permeability and Charge State)
Avdeef, A. (2001) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026013395100 · Cited by 587
Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions
Yu, L. X., Amidon, G. L., Polli, J. E., Zhao, H., Mehta, M. U., Conner, D. P., Shah, V. P., Lesko, L. J., Chen, M.-L., Lee, V. H. L., et al. (2002) · Pharmaceutical Research · doi:10.1023/a:1016473601633 · Cited by 571
Martinez, M. N., & Amidon, G. L. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00970002042006005 · Cited by 536
Fleisher, D., Li, C., Zhou, Y., Pao, L., & Karim, A. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936030-00004 · Cited by 506
The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Journal of Clinical Pharmacology · doi:10.1177/0091270003043005001 · Cited by 315
Yazdanian, M., Briggs, K., Jankovsky, C., & Hawi, A. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000016242.48642.71 · Cited by 290
Unmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4
Cummins, C. L., Jacobsen, W., & Benet, L. Z. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1036 · Cited by 289
Self-citationAbsorption Classification of Oral Drugs Based on Molecular Surface Properties
Bergström, C. A. S., Strafford, M., Lazorova, L., Avdeef, A., Luthman, K., & Artursson, P. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020986i · Cited by 247
Sasaki, M., Suzuki, H., Ito, K., Abe, T., & Sugiyama, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109081200 · Cited by 228
Human Jejunal Effective Permeability and Its Correlation with Preclinical Drug Absorption Models
LennernÄs, H. (1997) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1997.tb06084.x · Cited by 223
Effect of Common Excipients on Caco-2 Transport of Low-Permeability Drugs
Rege, B. D., Yu, L. X., Hussain, A. S., & Polli, J. E. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1127 · Cited by 206
Benet, L., Cummins, C., & Wu, C. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489389 · Cited by 188
Self-citationChris Lipinski discusses life and chemistry after the Rule of Five
Owens, J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02556-4 · Cited by 171
Huang, S. M., & Lesko, L. J. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004265367 · Cited by 163
Cummins, C. L., Salphati, L., Reid, M. J., & Benet, L. Z. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.044719 · Cited by 161
Self-citationBlume, H. H., & Schug, B. S. (1999) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(99)00076-7 · Cited by 152
Mandagere, A. K., Thompson, T. N., & Hwang, K.-K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010152k · Cited by 140
EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN
Sun, H. L., Huang, Y., Frassetto, L. A., & Benet, L. Z. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000521 · Cited by 128
Self-citationPolli, J. E., Yu, L. X., Cook, J., Amidon, G. L., Borchardt, R. T., Burnside, B. A., Burton, P. S., Chen, M., Conner, D. P., Faustino, P. J., et al. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20064 · Cited by 123
Sun, D., Yu, L. X., Hussain, M. A., Wall, D. A., Smith, R. L., & Amidon, G. L. (2004) · PubMed · Cited by 119
Gupta, S. K., Manfro, R. C., Tomlanovich, S. J., Gambertoglio, J. G., Garovoy, M. R., & Benet, L. Z. (1990) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1990.tb01868.x · Cited by 117
Self-citationLau, Y. Y., Wu, C., Okochi, H., & Benet, L. Z. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061770 · Cited by 110
Self-citationCummins, C. L., Jacobsen, W., Christians, U., & Benet, L. Z. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.058065 · Cited by 108
Self-citationCui, D., Booth-Genthe, C. L., Carlini, E., Carr, B., & Schrag, M. L. (2004) · PubMed · doi:10.1124/dmd.32.11 · Cited by 98
Cummins, C. L., Mangravite, L. M., & Benet, L. Z. (2001) · Pharmaceutical Research · doi:10.1023/a:1010914624111 · Cited by 94
Self-citationLennernäs, H., Knutson, L., Knutson, T. W., Hussain, A., Lesko, L. J., Salmonson, T., & Amidon, G. L. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00005-2 · Cited by 87
Lam, J. L., & Benet, L. Z. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.11.1311 · Cited by 85
Self-citationMidazolam Exhibits Characteristics of a Highly Permeable P-Glycoprotein Substrate
Tolle‐Sander, S., Rautio, J., Wring, S., Polli, J. W., & Polli, J. E. (2003) · Pharmaceutical Research · doi:10.1023/a:1023433502647 · Cited by 81
Waterbeemd, H. V. D. (1998) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(98)00051-7 · Cited by 78
Taub, M. E., Kristensen, L. L., & Frøkjær, S. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00015-5 · Cited by 77
Tannergren, C., Knutson, T., Knutson, L., & Lennernäs, H. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01722.x · Cited by 74
High-Fat Meals Increase the Clearance of Cyclosporine
Gupta, S. K., & Benet, L. Z. (1990) · Pharmaceutical Research · doi:10.1023/a:1015831408425 · Cited by 67
Self-citationWu, C., & Benet, L. Z. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1292 · Cited by 63
Self-citationDesign of drugs through a consideration of drug metabolism and pharmacokinetics
Smith, D. A. (1994) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03188921 · Cited by 34
Kanfer, I. (2002) · PubMed · Cited by 22
Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity.
Tannergren, C., Langguth, P., & Hoffmann, K. J. (2001) · PubMed · Cited by 21
Research works printed but not linked: 2
- 33. J. H. Chang and L. Z. Benet, Interplay of multiple transporters and glucuronidating enzymes in LLC-PK1 cell lines. AAPS PharmSci. 4: Abstract T3257 (2002).
- 39. Y. Y. Lau, H. Okochi, and L. Z. Benet, Role of hepatic uptake and efflux transporters in the disposition of atorvastatin. AAPS Journal 6: Abstract T2352 (2004).
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationLipids and Lipid-Based Formulations: Optimizing the Oral Delivery of Lipophilic Drugs
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2197 · Cited by 1,824
“In addition to the potential effect of lipidic excipients (primarily surfactants) on P-gp-mediated efflux, Benet and co-workers have recently suggested that high-fat meals could inhibit P-g”
BackgroundStrategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., & Onoue, S. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.032 · Cited by 1,181
Advances in Oral Drug Delivery
Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., & Ahmad, M. Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.618411 · Cited by 876
Metadata
- Authors
- Wu, C.-Y., & Benet, L. Z.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Benet, Leslie Z.
- ORCID
- Benet, Leslie Z.
- Venue
- Pharmaceutical Research
- Published
- 2005-01
- Volume
- 22
- Issue
- 1
- Pages
- 11-23
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2060992818
- Cited by
- 1,401
- References
- 53
- Citations by year
- 2026: 32 · 2025: 37 · 2024: 33 · 2023: 55 · 2022: 76 · 2021: 67 · 2020: 78 · 2019: 65 · 2018: 62 · 2017: 85 · 2016: 77 · 2015: 83 · 2014: 86 · 2013: 83 · 2012: 83
- FWCI
- 9.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- National Institutes of Health
- National Cancer Institute (CA72006, P01CA072006)
- National Institute of General Medical Sciences (R01GM036633, GM61390, GM-36633)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD40543, P01HD040543)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- Biopharmaceutics Classification System, oral drug absorption, solubility, permeability, efflux pumps, drug-drug interactions, bioavailability, food effect, transporter inhibition, transporter induction, drug metabolism
- MeSH terms
- Animals, Biological Transport, Biopharmaceutics, Pharmaceutical Preparations, Humans, Permeability, Predictive Value of Tests, Tissue Distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.